Dimensional Fund Advisors
ACRV icon

Dimensional Fund Advisors’s Acrivon Therapeutics ACRV Stock Holding History

Dimensional Fund Advisors’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.4K Hold
18,364
– – ﹤0.01% 3200
2025
Q4 		$44.3K Sell
18,364
-1,215
-6% -$2.64K ﹤0.01% 3216
2025
Q3 		$35.5K Sell
19,579
-2,625
-12% -$3.69K ﹤0.01% 3252
2025
Q2 		$26.4K Sell
22,204
-21,950
-50% -$30.1K ﹤0.01% 3261
2025
Q1 		$90K Buy
44,154
+7,091
+19% +$38.2K ﹤0.01% 3212
2024
Q4 		$223K Buy
37,063
+6,239
+20% +$45.3K ﹤0.01% 3146
2024
Q3 		$216K Buy
30,824
+20,758
+206% +$164K ﹤0.01% 3157
2024
Q2 		$58.4K Buy
+10,066
New +$81.1K ﹤0.01% 3298

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors's ACRV Position: Q1 2026 in Review

Dimensional Fund Advisors held its Acrivon Therapeutics (ACRV) position steady in Q1 2026 at 18,364 shares worth $25.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3200.

Dimensional Fund Advisors first reported a position in ACRV in Q2 2024 and has held it in 8 quarters since. The position peaked at $223K in Q4 2024. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • Dimensional Fund Advisors held 18,364 shares of Acrivon Therapeutics worth $25.4K as of Q1 2026.
  • Dimensional Fund Advisors left its Acrivon Therapeutics share count unchanged in Q1 2026.
  • Acrivon Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #3200 holding.
  • Dimensional Fund Advisors first reported a position in Acrivon Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Dimensional Fund Advisors's Acrivon Therapeutics position peaked at $223K in Q4 2024.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.